News
ASMB
13.41
+0.60%
0.08
Weekly Report: what happened at ASMB last week (0408-0412)?
Weekly Report · 5d ago
Weekly Report: what happened at ASMB last week (0401-0405)?
Weekly Report · 04/08 09:07
Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)
TipRanks · 04/03 05:52
H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)
TipRanks · 04/01 10:36
HC Wainwright & Co. Reiterates Neutral on Assembly Biosciences
Benzinga · 04/01 10:20
Weekly Report: what happened at ASMB last week (0325-0329)?
Weekly Report · 04/01 09:07
Assembly Biosciences Q4 EPS $(1.74) Beats $(2.88) Estimate, Sales $7.16M
Benzinga · 03/29 03:36
Assembly Biosciences GAAP EPS of -$13.38 beats by $0.90
Assembly Biosciences GAAP EPS of -$13.38 beats by $0.90. Revenues from collaborative research were $7.2 million for the year ended December 31, 2023. The company’s cash position is projected to fund operations into the second half of 2025.
Seeking Alpha · 03/28 21:03
Press Release: Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Assembly Biosciences reports financial results and recent highlights for the fourth quarter and year ended December 31, 2023. Four candidates planned to be in clinical development in 2024. The company has entered a long-term partnership with Gilead Sciences to advance its antiviral pipeline.
Dow Jones · 03/28 20:05
Press Release: Assembly Biosciences Reports -2-
Three months ended December 31, 2018, The Company's total liabilities and stockholders' equity are $ 101,794 million. The Company reported a net loss of $17.2 million for the quarter. The company has no debt and no liabilities. Three months ended September 30, 2018. The company's net loss for the year was $16.1 million.
Dow Jones · 03/28 20:05
ASMB Stock Earnings: Assembly Biosciences Misses EPS for Q2 2023
Assembly Biosciences reported earnings per share of -$3.84 for the second quarter of 2023. The company did not report any revenue for the quarter. Assembly B biosciences' earnings were below the analyst estimate for EPS of $3.48.
Investorplace · 03/25 16:52
Weekly Report: what happened at ASMB last week (0318-0322)?
Weekly Report · 03/25 09:07
Assembly Biosciences Inc <ASMB.OQ> expected to post a loss of $2.88 a share - Earnings Preview
Assembly Biosciences Inc expected to post a loss of $2.88 a share - Earnings Preview. The company is expected to show change in quarterly revenue when it reports results on March 20. LSEG's mean analyst estimate for the company is for a loss.
Reuters · 03/18 11:06
Weekly Report: what happened at ASMB last week (0311-0315)?
Weekly Report · 03/18 09:07
Assembly Biosciences Welcomes New Board Member, Launches Bonus Plan
TipRanks · 03/15 20:24
Weekly Report: what happened at ASMB last week (0304-0308)?
Weekly Report · 03/11 09:07
Weekly Report: what happened at ASMB last week (0226-0301)?
Weekly Report · 03/04 09:07
Weekly Report: what happened at ASMB last week (0219-0223)?
Weekly Report · 02/26 09:08
Assembly Biosciences (ASMB) Price Target Increased by 1100.00% to 36.72
NASDAQ · 02/24 00:14
Weekly Report: what happened at ASMB last week (0212-0216)?
Weekly Report · 02/19 09:08
More
Webull provides a variety of real-time ASMB stock news. You can receive the latest news about Assembly Bioscie through multiple platforms. This information may help you make smarter investment decisions.
About ASMB
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.